{"filings":[{"id":3432197,"accession_number":"0001493152-26-046863","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-10-13T21:00:46+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions adopts Second Amended and Restated Bylaws; majority-vote standard clarified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted the Second Amended and Restated Bylaws effective October 12, 2026, revising Section 2.6 on stockholder voting.","Non-director matters now decided by affirmative vote of a majority in voting power of votes cast; abstentions and broker non-votes are excluded and have no effect.","An investor presentation was made available October 13, 2026 via the Investors section of www.ibs.inc (furnished as Exhibit 99.1).","Exhibit 99.1 text was not appended to the filing, so no presentation figures, guidance or business updates can be reported.","Signed by CFO Spiro Sakiris; common stock (INBS) trades on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2825757,"accession_number":"0001493152-26-042411","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-09-11T21:00:21+00:00","items":["8.01"],"status":"ready","headline":"Intelligent Bio Solutions updates share count to 3,316,803 after warrant exercise and stock issuance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Exercise of 285,000 prefunded warrants increased outstanding common stock.","Issued 4,333 restricted shares under Feb 29, 2024 IR and corporate development advisory agreement.","Total shares outstanding as of Sept 10, 2026: 3,316,803.","Share count update filed as Item 8.01 other events; no financial impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2752036,"accession_number":"0001493152-26-041901","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-09-09T12:50:25+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions files FDA 510(k) for fingerprint drug screening codeine detection","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted 510(k) to FDA on Sept 9, 2026 seeking clearance for opiate codeine detection via fingerprint sweat analysis.","Method Comparison Study: accuracy >98%, sensitivity >94%, specificity 100%, verified by LC-MS/MS across 3 U.S. clinical sites.","Package includes 18 test reports, 170+ attachments, 15,000+ data lines from 18,000+ hours of data collection.","Precision testing: 1,600+ tests across 3 production runs and 3 sites; cut-off study in 40 adults vs FDA-cleared predicate.","Cybersecurity: 100% of medium-risk vulnerabilities remediated; all 19 SBOM vulnerabilities resolved with third-party verification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2633516,"accession_number":"0001493152-26-041253","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-09-02T21:00:27+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"INBS raises $5.0M private placement with warrants; potential $15M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2,036,659 shares (or pre-funded warrants) at $2.455 combined price; gross proceeds ~$5.0M.","Series N-1 warrants exercise at $2.33, callable after FDA 510(k) clearance; N-2 warrants after shareholder approval.","Placement agent Ladenburg Thalmann: 8% cash fee plus 5% warrant coverage (101,833 warrants).","Proceeds for working capital; resale registration statement due by Sept 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2606356,"accession_number":"0001493152-26-041055","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-09-01T21:10:28+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS reports 98.2% accuracy in codeine drug screen study; 510(k) submission on track for Sept 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Multi-site study across 3 U.S. clinical sites: 98.2% accuracy, 94.6% sensitivity, 100% specificity for opiate codeine.","Improvement from prior Nov 2024 study: ~94% accuracy and 82% sensitivity; specificity unchanged at 100%.","Results measured against validated LC-MS/MS reference method; 70 true positives, 144 true negatives, 0 false positives.","Company accelerated filing timeline; expects to submit 510(k) application in September 2026 for U.S. market entry.","CEO Harry Simeonidis: 'we now have everything we need for our 510(k) submission.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2550316,"accession_number":"0001493152-26-040656","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-08-28T21:20:26+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS furnishes business presentation via 8-K; no financials disclosed in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished a business update presentation on Aug 28, 2026, under Regulation FD.","Presentation is accessible on the Investors section of www.ibs.inc; no content excerpted in the filing.","No specific financial, operational, or strategic figures were included in the 8-K or exhibit text.","Investors must visit the company website to view the presentation; filing provides no summary details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2337876,"accession_number":"0001493152-26-039140","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-08-19T12:50:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"INBS reports FY2026 revenue up 38% to $4.2M; gross margin expands to 48.63%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2026 revenue $4.2M, up 38% YoY from $3.05M; gross profit $2.05M, up 64% YoY.","Gross margin 48.63%, up 778 bps from 40.85%; driven by Syrma Johari manufacturing transition.","Reader installed base 1,886 units (+22% YoY); consumable cartridges 106,500 (+35%); 502 active customers.","FDA 510(k) submission on track for H2 calendar 2026; all clinical data collection completed.","New strategic partnership with Bouygues UK for drug-testing rollout; eighth European patent granted."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":4215175.0,"consensus_period":"2026-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2192237,"accession_number":"0001493152-26-037206","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-08-11T21:29:49+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions completes final clinical study; FDA 510(k) submission on track for H2 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed multi-site Method Comparison Study; all clinical data collection for FDA 510(k) program now complete.","Study ran at 3 U.S. clinical sites over 3 weeks with CenExel; 135 participants and 9 operators enrolled.","Data analysis underway; all specimens independently verified via LC-MS/MS analysis.","FDA 510(k) submission targeted for H2 2026 for opiate codeine detection, ahead of planned U.S. market entry.","CEO Harry Simeonidis: milestone represents 'a substantial body of work and clinical evidence.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2061719,"accession_number":"0001493152-26-036112","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-08-05T12:55:18+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions completes usability study for FDA 510(k) submission for drug screening system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Study confirms system can be effectively administered by operators with no specialist background.","Study conducted with CenExel Clinical Research; 15 operators participated.","On track to submit 510(k) package in H2 2026 for U.S. market clearance for opiate codeine detection.","Part of broader submission program including cut-off, method comparison, interference, and precision studies.","Targets entry into the multi-billion-dollar U.S. drug screening market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2026797,"accession_number":"0001493152-26-035861","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-08-03T21:22:39+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS completes interference study; on track for 510(k) submission in H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed Interference Study for fingerprint drug screening system, testing common substances (hand creams, alcohol, oils, dirt, water) for impact on codeine detection.","Study conducted with CenExel Clinical Research, following FDA guidance and ICH GCP guidelines; data analysis underway with LC-MS/MS verification.","Company remains on track to submit FDA 510(k) package in calendar H2 2026 for U.S. market clearance for opiate codeine detection.","Part of comprehensive program including Cut-off Study, Method Comparison Study, precision and penetration testing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2026757,"accession_number":"0001493152-26-035860","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-08-03T21:20:35+00:00","items":["8.01"],"status":"ready","headline":"Intelligent Bio Solutions reports 3,018,188 shares outstanding as of July 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total outstanding common stock as of July 31, 2026: 3,018,188 shares.","Increase driven by ATM sales, warrant exercises, and restricted stock issuance under prior agreements.","No other material events or financial results disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1831639,"accession_number":"0001493152-26-034428","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-07-23T21:00:13+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions resolves all cybersecurity review items for FDA 510(k) submission; on track for H2 2026 filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed independent third-party penetration testing; all cybersecurity review items resolved.","100% of medium-risk vulnerabilities remediated; low-risk reduced from 11 to 2 with risk-based justification.","All 19 software bill of materials (SBOM) vulnerabilities fully resolved; documentation aligned with FDA guidance.","510(k) submission targeting codeine detection as initial indication; planned U.S. market entry in multi-billion-dollar drug screening market.","Manufacturing partnership with Syrma Johari MedTech expected to deliver >40% production cost savings and ~20 ppt gross margin improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1758116,"accession_number":"0001493152-26-034018","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-07-21T12:50:36+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions completes precision testing for FDA 510(k) submission for codeine detection","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Precision testing included over 1,600 tests across three production runs and three independent sites.","Results confirmed repeatable, reproducible performance, strengthening the FDA 510(k) submission package.","Submission targets U.S. market clearance for the Intelligent Fingerprinting Drug Screening System for opiate codeine.","Company plans U.S. launch after FDA 510(k) clearance, citing a multi-billion-dollar annual drug screening market.","CEO Harry Simeonidis stated the testing puts the company firmly on track for submission and launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1084759,"accession_number":"0001493152-26-028898","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-06-16T20:30:35+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions begins interference study for FDA 510(k) clearance of fingerprint drug test for codeine","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Interference Study with 75 healthy adults to validate the system's codeine specificity against everyday substances.","Expected completion by mid-July 2026; results will be part of the FDA 510(k) submission package.","Study runs concurrently with Method Comparison Study; follows January 2026 Cut-off Study.","Partners again with CenExel Clinical Research to conduct the clinical trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":788276,"accession_number":"0001493152-26-026780","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-06-02T12:48:18+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions starts multi-site FDA 510(k) study for opiate codeine fingerprint test","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Study will enroll 135 donor participants across multiple sites; partnered with CenExel Clinical Research.","Designed to validate accuracy, sensitivity, specificity of the Intelligent Fingerprinting Drug Screening System for workplace use.","Company expects to complete enrollment and data collection by end of July 2026.","User performance evaluation by non-laboratory personnel is a key part of the 510(k) submission.","Results will be confirmed via LC-MS/MS; study follows ICH GCP guidelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77004,"accession_number":"0001493152-26-022823","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-05-14T01:08:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Q3 revenue $1.06M (+46% YoY); cartridge sales up 59%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 cartridge revenue $703,538, up 59% YoY, representing 66% of total sales.","Gross profit margin expanded to 50.5% in Q3 (vs 46.8% prior year); nine-month margin 49.3%.","Nine-month revenue reached $3.07M, up 39% YoY; cash balance $6.86M at March 31, 2026.","Marketing spend in Q3 down 42% YoY while commercial momentum accelerated.","FDA 510(k) program advancing; new manufacturing partnership and Bouygues UK customer added."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":3069373.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95020,"accession_number":"0001493152-26-018002","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions reports 2,176,848 shares outstanding as of April 20, 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["As of April 20, 2026, total outstanding shares of INBS common stock were 2,176,848.","Increase resulted from exercise of previously issued warrants and sales under the At Market Offering Agreement with Ladenburg Thalmann.","Update reflects changes since the prior 8-K filed March 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107795,"accession_number":"0001493152-26-012173","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Intelligent Bio grants restricted shares to CEO/CFO/directors; updates ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Harry Simeonidis and CFO Spiro Sakiris each receive 9,150 time-vesting and 21,350 performance-vesting restricted shares.","Directors awarded 20,000 time-vesting shares; non-executive employees get 10,500 time-vesting and 24,500 performance-vesting shares.","Total outstanding shares as of March 23, 2026: 2,001,173, reflecting grants and warrant exercises.","Up to $3,966,316 in shares available for sale under existing ATM agreement with Ladenburg Thalmann; new prospectus supplement filed.","Performance-vesting shares tied to clinical trial, FDA submission, and commercial milestones; vest over up to 10 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107794,"accession_number":"0001493152-26-007973","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS ships first readers from new partner Syrma Johari; expects 40%+ cost savings, 20ppt gross margin boost","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First Intelligent Fingerprinting Drug Screening Readers manufactured by Syrma Johari MedTech deployed to U.K. and Europe customers.","Partnership expected to deliver annual production cost savings over 40%, improving gross margin by ~20 percentage points annually.","In-house lateral flow test strip production capacity doubled, enabling faster R&D and expanded drug panels.","Company confirms planned U.S. market entry (beyond Forensic Use Only) later in 2026, supported by scaled manufacturing capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107793,"accession_number":"0001493152-26-006317","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions Q2 revenue $896,774, up 48% YoY; reader sales surge 104%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $896,774, up 48% YoY; reader sales $246,519 (+104%), cartridge sales $516,754 (+33%).","First-half FY2026 revenue $2.01M (+36% YoY); gross margin improved to 49% from 39%.","Closed $10M private placement (net $9.4M received Jan 2, 2026) for working capital and FDA 510(k) submission.","Initiated additional clinical studies for FDA 510(k); plans for U.S. market entry.","Strategic alliance with Vlepis Pty Ltd for consumer health monitoring; major industrial service contract."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":2008571.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107792,"accession_number":"0001493152-26-005210","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio sees 48% Q2 revenue growth YoY, H1 revenue tops $2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fiscal Q2 2026 revenue expected up ~48% YoY; readers more than double (+104% YoY).","H1 2026 total revenue ~$2.01M (+36% YoY); cartridge sales +38%, readers +50%.","CEO cites expanding installed base as foundation for recurring cartridge revenue.","Company expects to file 10-Q for Q2 ended Dec 31, 2025 during week of Feb 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":2008571.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107791,"accession_number":"0001493152-26-004068","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions starts clinical studies for FDA 510(k) submission to detect codeine via fingerprint","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Partnered with Cliantha Research for a study in 40 adults to establish codeine detection cut-off levels.","Study uses Intelligent Fingerprinting Drug Screening System with DSR-Plus reader; full data analysis expected by end of March 2026.","Data will support FDA 510(k) submission and planned commercial launch into the multi-billion-dollar U.S. drug screening market.","Company notes over 500,000 tests already sold outside the U.S.; targeting workplace, clinical, and law enforcement segments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107790,"accession_number":"0001493152-26-000984","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Intelligent Bio Solutions regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 7, 2026 confirming compliance with Bid Price Rule.","Stock closed at or above $1.00 for 14 consecutive business days through Jan 6, 2026.","Deficiency notice from Dec 16, 2025 cited bid price below $1.00 for 30 days.","Compliance achieved; matter closed by Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107789,"accession_number":"0001493152-26-000176","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions closes $10M private placement; funds FDA submission and expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$10M from sale of 2,298,850 units at $4.35/unit (common/pre-funded warrant + two Series K warrants).","At closing, 105,000 shares and 2,193,850 pre-funded warrants issued; post-closing shares outstanding ~1.2M (excluding warrants).","Series K warrants exercisable at $4.10/share for 5 years after registration statement declared effective by SEC.","CEO: proceeds to fund FDA 510(k) submission for fingerprint drug screening system and international market expansion.","Closing on Jan 2, 2026; resale registration statement to be filed by Jan 10, effective by Feb 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124191,"accession_number":"0001493152-25-029812","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions partners with Syrma Johari Medtech for manufacturing; expects ~20ppt gross margin improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership with Syrma Johari Medtech to scale production of fingerprint drug screening reader; expects annual production cost savings >40%.","Company anticipates ~20 percentage point improvement in gross margin compared to previous arrangement.","Syrma Johari's manufacturing capacity ~4x current; supports planned U.S. market entry in 2026.","Syrma Johari operates 14 manufacturing locations, certified to ISO 13485, MDSAP, FDA, TUV SUD, GMP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124190,"accession_number":"0001493152-25-028003","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq deficiency letter for bid price non-compliance; 1-for-10 reverse stock split effected","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Dec 15 for closing bid price below $1 for 30 consecutive business days.","Initial compliance period runs through June 15, 2026; cure if bid price ≥ $1 for 10 consecutive days.","Filed and effected a 1-for-10 reverse stock split on Dec 15; split-adjusted trading began Dec 16.","If non-compliant by June 15, may qualify for an additional 180-day period if meeting other listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124189,"accession_number":"0001493152-25-027534","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions announces 1-for-10 reverse stock split effective Dec 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split approved by stockholders Oct 16, 2025; ratio set by Board at 1-for-10.","Shares outstanding to reduce from ~9.6M to ~0.96M; authorized shares unchanged at 100M.","No fractional shares; cash in lieu paid based on 5-day VWAP preceding split date.","Trading symbol INBS unchanged; new CUSIP 36151G709; split-adjusted trading starts Dec 16.","Historical net loss per share retroactively adjusted: FY2025 basic EPS becomes $(20.04) from $(2.00)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124188,"accession_number":"0001493152-25-025665","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions furnishes investor presentation for Dec 2, 2025; content not disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made a presentation available on its website under Investors section.","Presentation relates to business and operations, but specific details not provided in filing.","Filing is under Regulation FD; presentation is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124187,"accession_number":"0001493152-25-025410","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Intelligent Bio Solutions issues 75,000 restricted shares to MDM for advisory services","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved issuance of 75,000 restricted shares of common stock (par value $0.01) to MDM Worldwide Solutions, Inc.","Shares issued as compensation for strategic communication advisory services under engagement letter effective Sept 11, 2025.","No cash proceeds received; shares issued in reliance on Section 4(a)(2) exemption from registration.","Issuance date of board approval: November 25, 2025; filing date: November 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124186,"accession_number":"0001493152-25-022005","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions reports record Q1 revenue of $1.11M, up 28% YoY; gross margin expands to 46.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.11M (+28% YoY, +32% sequential); cartridge sales 57.6% of total revenue.","Gross margin 46.6%, up 690 bps YoY, citing operational efficiency and product mix.","Added 33 new customer accounts; total active accounts 492 across 24+ countries.","Secured major contract with London public transport operator covering 14 sites and 4,400+ staff.","Expanded portfolio with SmarTest® Patch and global distribution deal with SMARTOX®."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1111797.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124185,"accession_number":"0001493152-25-021323","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions reports preliminary Q1 FY2026 revenue over $1M, up ~32% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary revenue >$1M for fiscal Q1 ended Sep 30, 2025; third consecutive quarter of growth.","Revenue up ~32% sequentially and ~28% year-over-year.","Cartridge revenue up ~43% YoY; reader revenue up ~23% YoY.","Growth driven by new customer accounts and strong sales of both cartridges and readers.","Full Q1 financial results expected in 10-Q filing week of Nov 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1111797.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124184,"accession_number":"0001493152-25-020262","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS adds 33 new customer accounts in Q1 FY2026, up 50% YoY; total active accounts exceed 480","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Added 33 new customer accounts in fiscal Q1 ended Sept 30, 2025, a 50% increase YoY.","Total active accounts reached over 480; growth driven by maritime, transport, logistics, and new government sector.","91% of new accounts were first-time adopters; 9% expanded use within existing organizations.","Strong UK growth supported by distributor expansion across Europe and Middle East.","Global drug screening market projected at $17.1B by 2029, 15% CAGR, supporting INBS's expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124183,"accession_number":"0001493152-25-018806","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Intelligent Bio Solutions stockholders approve reverse stock split, warrant share issuance, and incentive plan expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected four directors: Boyages, Hurd, Isenberg, Fraser. Boyages received 1,349,921 for, 503,182 withheld.","Approved amendment to 2019 Long Term Incentive Plan, increasing authorized shares from 1.3M to 1.795M (495,000 new shares).","Approved issuance of up to 4,147,616 shares upon warrant exercise (over 20% of outstanding common stock).","Approved reverse stock split at ratio of 1-for-2 to 1-for-10 within 12 months, at Board's discretion, to regain Nasdaq bid price compliance.","Ratified UHY LLP as independent auditor for fiscal year ending June 30, 2026 (4,246,183 for, 227,964 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140855,"accession_number":"0001493152-25-015068","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions updates FDA 510(k) timeline; clearance expected H2 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Will commence clinical studies before year-end to gather additional data for FDA 510(k) resubmission for codeine fingerprint test.","Anticipates FDA 510(k) clearance for opiate codeine use in the second half of 2026.","Drug screening system adopted by over 450 accounts in 24 countries with 18 distribution partners.","Currently marketed outside U.S. and for forensic use only; FDA clearance would open broader U.S. commercial entry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140854,"accession_number":"0001493152-25-014961","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions extends Series H-1 warrant expiration to March 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved extension of Series H-1 Warrant termination date from Sept 27, 2025 to March 27, 2026.","Warrants cover 1,034,213 shares of common stock held by six warrant holders who consented.","Exercise prices and all other warrant terms remain unchanged; no consideration received for extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140853,"accession_number":"0001493152-25-013836","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions must resubmit FDA 510(k) for drug screening system after new info request","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requested new additional information in a letter dated September 12, 2025, requiring a new 510(k) resubmission.","Company previously responded to a February 2025 AI request covering over 70 items and submitted additional data in August 2025.","First-of-its-kind sweat-based device; FDA feedback described as not uncommon for breakthrough technologies.","Company expects an investor update within ten days outlining a revised timeline for FDA clearance.","International commercial activities continue to grow outside the U.S. while pursuing clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140852,"accession_number":"0001493152-25-012101","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions Q4 revenue up 16% YoY to $844K; progress on FDA 510(k) for U.S. market","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 FY2025 revenue $843,884 (+16% YoY); cartridge sales up 24% YoY.","Added 115 new accounts in FY2025; active base >450 across 24 countries with 18 distributors.","FDA 510(k) submission in progress for opiate test system; seeking U.S. clearance beyond Forensic Use Only.","Operational improvements: multilingual system, HubSpot CRM, new U.S. patent; accounting system upgrade underway.","Net loss or EPS not disclosed; company reports 'reduced net loss' but no specific figures."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3052532.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140851,"accession_number":"0001493152-25-011706","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions preliminary Q4 revenue up ~16% sequentially and YoY, driven by cartridge sales","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 FY2025 revenue growth of ~16% sequentially and year-over-year, driven by higher-margin cartridge sales and account growth.","Submitted FDA 510(k) application for opiate test system (codeine) to support planned U.S. market entry.","Completed multilingual system upgrades and launched localized websites to strengthen global adoption across Europe, Middle East, and Latin America.","Full-year FY2025 results and Form 10-K expected to be filed during the week of August 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3052532.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140850,"accession_number":"0001493152-25-011634","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"INBS submits FDA 510(k) AI response; expects clearance decision within six weeks","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted over 1,900 pages including 23 detailed test reports and 7,800 data lines from 10,000 hours of testing.","New cybersecurity and performance data reinforce fingerprint sweat drug screening platform for U.S. market entry in 2025.","Company serves 450+ accounts in 24 countries with 18 global distribution partners.","FDA response anticipated within six weeks.","CEO calls U.S. market entry a top priority given multi-billion-dollar commercial opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140849,"accession_number":"0001641172-25-021200","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions raises $3.8M via warrant exercise inducement, funds FDA 510k filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$3.8M from exercise of existing Series G and H-1 warrants at $1.90/share; closing July 28, 2025.","Holders get new Series J warrants for up to 4,046,456 shares at $1.90, exercisable upon stockholder approval, expiring 5.5 years from issuance.","Net proceeds to fund completion of 510k filing with FDA for Fingerprint Drug Screening System and general working capital.","Company issued 1,545,494 common shares via warrant exercise and amended H-1 warrants for 477,734 shares at $0.01/share.","Outstanding shares as of July 24, 2025: 7,433,658, including recent ATM and restricted stock issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140848,"accession_number":"0001641172-25-020729","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS strengthens FDA 510(k) with new fingerprint sweat detection data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cybersecurity penetration and EMC testing completed to validate platform resilience.","Ultra-Micro Balance scale confirmed ability to detect sweat volumes down to 0.0000001g.","Over 6,000 hours invested in testing, data aggregation, and analysis for submission.","Plan to submit findings to FDA in August, targeting U.S. market entry in 2025.","Company supports 450+ accounts across 24 countries with 18 distribution partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140847,"accession_number":"0001493152-25-011264","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions signs global distribution deal with Smartox for SmarTest Patch outside U.S. and Canada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership with Smartox LLC to distribute SmarTest Patch in international markets excluding U.S. and Canada.","SmarTest Patch provides continuous sweat-based drug detection for justice, rehabilitation, and workplace sectors.","INBS currently serves over 450 active accounts in 24 countries; deal adds complementary technology.","FDA clearance remains a strategic priority for U.S. expansion beyond forensic use only.","Global drug testing market projected to reach ~$18.6B by 2030 (Grand View Research)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140846,"accession_number":"0001641172-25-019745","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions adds SmarTest Patch wearable for extended drug detection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SmarTest Patch is a wearable device that continuously detects drugs via sweat over 7–10 days.","Developed by Smartox LLC; complements INBS's existing fingerprint sweat drug test.","Targets longer detection windows for justice, rehabilitation, and non-U.S. markets.","Detects cocaine, opiates, methamphetamines, marijuana, fentanyl, among others.","Expands product offering to address both short- and long-term testing needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140845,"accession_number":"0001641172-25-017814","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Intelligent Bio Solutions amends CEO & CFO employment agreements, raises salaries","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO salary increased from AUD 560,000 to AUD 580,000; CFO from AUD 410,000 to AUD 430,000, effective June 30, 2025.","Enhanced severance: on termination without cause, 100% bonus and full equity vesting; after Change in Control adds 2x salary.","Non-compete revised to tiered restricted period (24 to 1 month) and broadened scope to prohibit any interest in competing entities.","Change in Control defined as acquisition of >20% voting stock, certain mergers, asset sale, or Board composition change, excluding stock repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158596,"accession_number":"0001641172-25-011176","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"INBS surpasses 450 accounts; expands fingerprint drug testing into luxury marine, retail, and waste sectors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 450 active accounts globally, with 35 new accounts added in fiscal Q3.","Expanded into luxury marine sector in Europe, retail (major e-commerce) and waste/recycling in Australia.","Distributor network now includes 18 partners across 19 countries for localized support.","Plans to introduce a collected testing service to provide flexibility for high-volume customers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158595,"accession_number":"0001641172-25-010006","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","5.02","5.07","9.01"],"status":"ready","headline":"Intelligent Bio Solutions Q3 revenue $0.73M, up 20% QoQ; gross profit up 91% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.73M in fiscal Q3, up 20% sequentially; nine-month revenue $2.21M, down 7% YoY.","Gross profit $341,368, up 91% YoY; cartridge sales now 58% of total revenue for nine months.","Net loss attributable to company $2.54M, down from $2.98M YoY; cash $2.81M.","Added 35 new accounts in Q3, active customers exceed 450; launched multilingual system upgrades."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":2641687.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176999,"accession_number":"0001641172-25-000789","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions granted 6th U.S. patent for drug screening cartridge; plans 2025 U.S. market entry","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Granted U.S. Patent No. 12259385 covering lateral flow test strip in fingerprint drug screening cartridge.","This is the company's sixth active U.S. patent, strengthening IP protection for its drug screening technology.","CEO states patent validates innovative tech; company plans U.S. market entry in 2025 following Dec 2024 FDA 510(k) submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176998,"accession_number":"0001641172-25-000626","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions' FDA clearance process on track for 2025 U.S. launch","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["510(k) submitted Dec 18, 2024; FDA issued Additional Information request, pausing 90-day review clock.","Company responding to AI request; clearance expected within 3–6 months or longer if additional data needed.","System demonstrated 94.1% accuracy in method comparison study; PK data closely aligned to blood at 95% confidence level.","Targeting opiate test system for codeine; full panel already in 19 countries with over 400 accounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176997,"accession_number":"0001641172-25-000172","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Intelligent Bio Solutions expects sixth U.S. patent for fingerprint drug testing technology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expected patent will protect lateral flow technology core to its drug screening system.","Patent strengthens IP portfolio as company plans U.S. market entry in 2025.","CEO Harry Simeonidis states protection is critical for scaling U.S. footprint.","Recent FDA 510(k) submission supports non-invasive sweat-based testing approach.","INBS provides non-invasive alternative to traditional drug screening methods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176996,"accession_number":"0001493152-25-010372","cik":1725430,"company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Intelligent Bio Solutions sets 2024 annual meeting for May 8, 2025; proposal deadline March 24","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Annual Meeting to be held virtually on or about May 8, 2025.","Record date for voting set as March 18, 2025.","Stockholder proposals and director nominations must be received by March 24, 2025.","Deadline applies to both Rule 14a-8 proposals and other business under bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5812185.253012048,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-03-14T23:59:59+00:00|176996"}